Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alar PharmaceuticalsROCO:6785 -1.21%56 Quick Ratio is 38.77 as of Jun. 2026, which is at its 10-year median of 38.77. GuruFocus rates ROCO:6785 with a GF Score™ of 56/100 and a GF Value™ of NT$91.85 (Fairly Valued). The stock has 1 warning sign investors should review. Among 995 Drug Manufacturers companies, Alar Pharmaceuticals ranks better than 99.3% on this metric.
Alar Pharmaceuticals (ROCO:6785) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Alar Pharmaceuticals Quick Ratio Related Terms
Alar Pharmaceuticals Quick Ratio Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Alar Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alar Pharmaceuticals (ROCO:6785) has a Quick Ratio of 38.77 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Alar Pharmaceuticals and its competitors. This is near median its historical median of 38.77. Over the past decade, Alar Pharmaceuticals' Quick Ratio has ranged from 1.62 to 143.31. According to the industry distribution chart, Alar Pharmaceuticals ranks #7 out of 995 companies in the Drug Manufacturers industry, placing it in the top 0.7%.
Is Alar Pharmaceuticals' Quick Ratio too high?
Alar Pharmaceuticals' current Quick Ratio of 38.77 is near median its 10-year median of 38.77. Over the past 10 years, this metric has ranged from a low of 1.62 to a high of 143.31. The Drug Manufacturers industry median Quick Ratio is 1.43. Alar Pharmaceuticals' value of 38.77 is 2611.2% above this industry median. Based on the distribution chart, Alar Pharmaceuticals ranks #7 out of 995 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alar Pharmaceuticals has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #7 out of 995 companies for Quick Ratio. This places Alar Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.43. Alar Pharmaceuticals' value of 38.77 is 2611.2% above this benchmark. Historically, Alar Pharmaceuticals' own Quick Ratio has ranged from 1.62 to 143.31 over the past decade. While the company's 10-year median is 38.77 vs. the industry median of 1.43, Alar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.43, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alar Pharmaceuticals's current Quick Ratio of 38.77 is 2611.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Alar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alar Pharmaceuticals's current Quick Ratio is 38.77, which is near median its own 10-year median of 38.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Fairly Valued. The stock's GF Value™ is NT$91.85, compared to a current price of NT$98.10 — trading 6.8% above its estimated fair value. The current Quick Ratio is 38.77, which is near median its 10-year median of 38.77 and 2611.2% above the Drug Manufacturers industry median of 1.43. Alar Pharmaceuticals' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Quick Ratio is 38.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$98.10 is trading 6.8% above its estimated GF Value™ of NT$91.85.
GuruFocus considers Alar Pharmaceuticals to be Fairly Valued.
Key valuation signals for ROCO:6785:
Quick Ratio: 38.77 (near median its 10-year median of 38.77)
GF Value™: NT$91.85 vs. price of NT$98.10 (6.8% above fair value)
Industry Position: 2611.2% above the Drug Manufacturers median (#7 of 995)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
56GF Score
Get the complete analysis for ROCO:6785
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
